Abstracts tagged "Clinical practice"

Abstract Number: 1517 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Retention Rate of Certolizumab Pegol in Spondyloarthritis. Real Life Data
Rosa Expósito¹, Carlos M Gonzalez², Rosa García-Portales³, Ana Urruticoechea-Arana⁴, Jose Ramon Lamua⁵, Maria del Pilar Navarro⁶, José Santos Rey Rey⁷ and Manuel Fernández⁸, ¹Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ²Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital Virgen de la Victoria, Málaga, Spain, ⁴Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁵Hospital del Henares, Madrid, Spain, ⁶Hospital de Fuenlabrada, Fuenlabrada, Spain, ⁷Hospital Virgen de la Salud, Toledo, Spain, ⁸H. Guadalajara, Guadalajara, Spain
Background/Purpose: Certolizumab pegol (CZP) is available for patients with spondyloarthritis (SpA), including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axialSpA). CZP has a different molecular…
Abstract Number: 433 • 2017 ACR/ARHP Annual Meeting
Predictors of Earlier Biologic Initiation Among Patients with Rheumatoid Arthritis Starting Methotrexate
Michael D. George¹, Brian Sauer², Chia-Chen Teng, MS², Grant Cannon², Bryant R. England³, Gail S. Kerr⁴, Ted R. Mikuls⁵ and Joshua Baker⁶, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴VAMC, Georgetown University, Washington, DC, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Biologic therapy for the treatment of RA has increased dramatically and has substantially increased costs of care. This study aimed to identify factors associated…
Abstract Number: 1548 • 2017 ACR/ARHP Annual Meeting
Opioid Use in Patients with Ankylosing Spondylitis
Victor S. Sloan¹, Anna Sheahan¹, Jeffrey Stark² and Robert Y. Suruki¹, ¹UCB Pharma, Raleigh, NC, ²UCB Pharma, Smyrna, GA
Background/Purpose: The use or misuse of opioids has become a major public health issue in the USA. It is estimated that the economic burden of…
Abstract Number: 538 • 2017 ACR/ARHP Annual Meeting
Severe Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
Lydia A Alcazar¹, Judit Font Urgelles², Cynthia Milagros León Cárdenas², Cristina Vadillo Font², Dalifer Freites Núñez¹, Leticia Leon¹, Juan A Jover Jover² and Zulema Rosales Rosado^1,2, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. It is…
Abstract Number: 1555 • 2017 ACR/ARHP Annual Meeting
Treatment Changes By Joint Activity and Skin Severity in Patients with Comorbid Psa and Pso
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Treatment of both joint and skin symptoms is important for overall disease management of patients with psoriatic arthritis and comorbid psoriasis1,2. The objective of…
Abstract Number: 607 • 2017 ACR/ARHP Annual Meeting
Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression up to 52 Weeks: An Overview from Secukinumab Phase 3 Clinical Trials
Philip J Mease¹, Mark Lebwohl², Isabelle Gilloteau³, Todd Fox³, Jaime Oliver³, Steffen Jugl³ and Alice B Gottlieb⁴, ¹University of Washington School of Medicine and Swedish Medical Center, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Novartis Pharma AG, Basel, Switzerland, ⁴Department of Dermatology, New York Medical College, Vallhalla, NY
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody selectively neutralizing interleukin-17A, exhibits significant efficacy, with a favorable safety profile, in the treatment of psoriatic arthritis…
Abstract Number: 1559 • 2017 ACR/ARHP Annual Meeting
Residual Disease Activity in Psoriatic Arthritis Triggers Treatment Adjustment in Only a Quarter of Patients in Daily Clinical Practice
Leonieke van Mens¹, Sadaf Atiqi², Inka Fluri², Marleen van de Sande³, Arno van Kuijk⁴ and Dominique Baeten¹, ¹AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ³Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: With expanding therapeutic possibilities for the treatment of psoriatic arthritis (PsA) it will be increasingly important to determine residual disease and define when to…
Abstract Number: 743 • 2017 ACR/ARHP Annual Meeting
Impact of Detect on Right Heart Catheterization Referral and Results; Data from a Prospective, Unselected, Systemic Sclerosis Cohort
Anna-Maria Hoffmann-Vold¹, Håvard Fretheim², Anders Heiervang Tennøe², Oyvind Midtvedt², Torhild Garen², Einar Gude², Arne K Andreassen² and Øyvind Molberg², ¹Division of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway
Background/Purpose: The DETECT calculator has been freely available as a tool for earlier detection and diagnosis of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc)…
Abstract Number: 1690 • 2017 ACR/ARHP Annual Meeting
Nailfold Capillary Counts Are Associated with Clinical Manifestations in Connective Tissue Disease Japanese Patitents
Atsushi Kondo¹, Tomohiro Kameda¹, Miharu Izumikawa¹, Hiromi Shimada², Shusaku Nakashima¹, Risa Wakiya¹, Mikiya Kato¹, Norimitsu Kadowaki¹ and Hiroaki Dobashi¹, ¹Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan, ²Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: Connective tissue diseases (CTD) patients have various clinical manifestation including pulmonary hypertension (PH) and digital ulcer (DU). Especially, Raynaud’s phenomenon (RP) is one of…
Abstract Number: 816 • 2017 ACR/ARHP Annual Meeting
Comparison between Giacta Trial and a Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice with Tocilizumab
Nuria Vegas-Revenga¹, Javier Loricera¹, Antonio Mera², Eva Pérez- Pampín², Santos Castañeda³, Lucia C. Domínguez-Casas¹, José Luis Martín-Varillas⁴, Belén Atienza-Mateo⁴, MC Gonzalez-Vela¹, Jose L. Hernández⁵, Miguel Angel González-Gay⁴ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Complejo Hospitalario Universitario de Santiago. Galicia. Spain, Santiago de Compostela, Spain, ³Hospital Universitario de La Princesa, Madrid. Spain, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁵Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: GiACTA study is a randomized, phase III controlled clinical trial of tocilizumab (TCZ) in giant cell arteritis (GCA) (1,2). Our aim was to compare…
Abstract Number: 2059 • 2017 ACR/ARHP Annual Meeting
Allopurinol Dose-Titration Patterns Relative to Serum Uric Acid Levels in Gout Patients: US Electronic Health Record Data
An-Chen Fu, Douglas C.A. Taylor and David S. Reasner, Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by elevated serum uric acid (sUA). Allopurinol is a first-line urate-lowering therapy…
Abstract Number: 1046 • 2017 ACR/ARHP Annual Meeting
Biological and Targeted Synthetic Dmards’ Prior Authorization Time Is Significantly Reduced with Pharmacy Presence in the Rheumatology Clinic
Wendy Ramey¹, Kristine M. Lohr², Matt Zeltner¹, Haley Herrell Postonl¹, Andrew Johannemann¹, Aric D. Schadler¹ and Aleksander Lenert³, ¹University of Kentucky, Lexington, KY, ²Rheumatology, University of Kentucky, Lexington, KY, ³Internal Medicine, Div. of Rheumatology, University of Kentucky, Lexington, KY
Background/Purpose: Treatment with biological DMARDs (bDMARD) and targeted synthetic DMARDs (tsDMARD) has led to improved outcomes for chronic rheumatic diseases. Current treat-to-target (T2T) strategy relies…
Abstract Number: 2452 • 2017 ACR/ARHP Annual Meeting
In Real-World Clinical Practice, Patients Switching from IV to SC Abatacept Maintain Clinical Efficacy after Switch
Rieke Alten¹, HM Lorenz², X Mariette³, H Nüßlein⁴, M Galeazzi⁵, F Navarro⁶, M Chartier⁷, J Heitzmann⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³Université Paris-Sud, Paris, France, ⁴University of Erlangen-Nuremberg, Nuremberg, Germany, ⁵University of Siena, Siena, Italy, ⁶Hospital Universitario Virgen Macarena, Seville, Spain, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: Patients (pts) with RA may be able to switch from IV to SC abatacept with no loss of efficacy or safety concerns, but data…
Abstract Number: 1078 • 2017 ACR/ARHP Annual Meeting
Initial Combination Therapy Versus Step-up Therapy Is More Effective and Less Costly As a Treat to Target Strategy for RA: A Markov Model Based upon the Dutch Rheumatoid Arthritis Monitoring Registry Cohorts
Celine J. van de Laar¹, Laura M.M. Steunebrink², Martijn A.H. Oude Voshaar³ and Harald E. Vonkeman⁴, ¹Transparency in Healthcare B.V., Hengelo, Netherlands, ²Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³University of Twente, Department of Psychology, Health and Technology, Enschede, Netherlands, ⁴koningsplein, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands
Background/Purpose: Adjusting medication of patients with rheumatoid arthritis (RA) until predefined disease activity targets are met, i.e. Treat to Target (T2T), is the currently recommended…
Abstract Number: 2530 • 2017 ACR/ARHP Annual Meeting
Clinical Specialty Setting As a Determinant for Disease Management in Patients with Psoriatic Arthritis: An Interim Analysis of the Cross-Sectional Observational Study
Wolf-Henning Boehncke¹, Rudolf Horváth², Ediz Dalkiliç³, Sȏnia A L Lima⁴, Masato Okada⁵, Maja Hojnik⁶, Fabiana Ganz⁷ and Ennio Lubrano⁸, ¹Geneva University Hospital and University of Geneva, Geneva, Switzerland, ²Department of Pediatric and Adult Rheumatology, University Hospital Motol, Prague, Czech Republic, ³Department of Internal Medicine, Division of Rheumatology, Uludag University School of Medicine, Gorukle, Bursa, Turkey, ⁴ABC Medical School, Santo André, Brazil, ⁵Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁶AbbVie, Ljubljana, Slovenia, ⁷AbbVie AG, Baar, Switzerland, ⁸Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy
Background/Purpose: Evidence suggests that timely and effective management can improve long-term outcomes in patients (pts) with psoriatic arthritis (PsA); however factors influencing treatment management decisions…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].